NCT04194827View on ClinicalTrials.gov

Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring

PHASE4RecruitingINTERVENTIONAL
Enrollment

267

Participants

Timeline

Start Date

March 1, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Rheumatoid Arthritis
Interventions
DIAGNOSTIC_TEST

Adalimumab serum trough concentration

Dose reduction based on adalimumab serum trough concentration

DIAGNOSTIC_TEST

Disease activity

Dose reduction based on adalimumab diseas activity

DRUG

Adalimumab

Adalimumab

Trial Locations (1)

1056AB

RECRUITING

Reade Rheumatology Research Institute, Amsterdam

All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

Sint Maartenskliniek

OTHER

lead

Reade Rheumatology Research Institute

OTHER